PRF Technologies Advances Healthcare and AI Energy Platforms with Key Milestones
Event summary
- FDA cleared IND for OcuRing™-K, enabling a Phase II trial in cataract surgery with patient enrollment expected in H2 2026.
- PRF-110 matched ZYNRELEF's 72-hour analgesic activity using a ropivacaine-only, NSAID-free formulation.
- DeepSolar validated Predict™, expanded into battery storage, and unveiled GridFeed™, backed by a strengthened balance sheet.
- Company ended June 2026 with $11.6 million in cash, nearly triple year-end 2025 levels.
The big picture
PRF Technologies is making strategic progress in both healthcare and AI-driven energy optimization. The FDA clearance for OcuRing™-K and the validation of PRF-110's analgesic activity strengthen its position in the post-surgical pain management market. Meanwhile, DeepSolar's expansion into battery storage and the unveiling of GridFeed™ position the company at the forefront of renewable energy trading and optimization. With a significantly strengthened balance sheet, PRF is well-positioned to capitalize on these advancements.
What we're watching
- Clinical Progress
- The pace at which OcuRing™-K Phase II trial enrollment and results will validate its potential in cataract surgery.
- Market Differentiation
- Whether PRF-110's NSAID-free formulation can position it as a leading non-opioid post-surgical pain management option.
- Commercial Scaling
- How DeepSolar's expansion into battery storage and the launch of GridFeed™ will drive revenue growth and market adoption.
Related topics